checkAd

     439  0 Kommentare VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE

    Vifor Pharma Ltd. / VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

    Lesen Sie auch

    In 2017 vifor pharma recorded a strong financial performance driven by its three medium-term strategic growth-drivers and the successful divesTiture of its non-core wholesale/retail PHARMACY business via an IPO. the company exceeded all elements of its guidance, which it raised at the Half-year 2017 reporting. strong growth is expected to continue in 2018 and beyond.

    Financial performance – strong growth trend continues • Significant revenue growth, with net sales of CHF 1,342.1 million, up 15.2% on a constant currency basis • Reported EBITDA excluding launch and ramp-up costs of Veltassa® increased to CHF 511.8 million, up 17.7% • Strong growth momentum continued in H2 for our three key medium-term strategic growth drivers, Ferinject®, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Veltassa® • Strong balance sheet and liquidity position with cash net of debt of CHF 191.1 million • All three components of our guidance, which we raised on 8 August 2017, were exceeded Three medium-term strategic growth-drivers on track • Reported net sales of Ferinject® /Injectafer® up 24.6% • Initiation of first Ferinject® study (AFFIRM-AHF) in acute heart failure • Velphoro® net sales increase of 48.6% • Post-period end avacopan conditional marketing authorization application accepted for regulatory review in Europe • Reported net sales of Veltassa® in its second year post-launch of CHF 51.7 million • Veltassa® approved in the 28 EU countries plus Norway, Liechtenstein, Iceland, Switzerland and Australia for the treatment of hyperkalaemia in adults Significant partnering and licencing deals concluded • Territory rights to avacopan (CCX168) expanded to everywhere outside the US and China • Agreement with Akebia Therapeutics to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the US • Exclusive rights to develop and commercialise avacopan (CCX168) in Japan granted to Kissei Pharmaceutical Co., Ltd. • Exclusive license agreement for commercialisation of Mircera® in the US expanded Milestone 2020 strategic plan on track • Galenica Santé successfully divested via an initial public offering on SIX Swiss Exchange • Investments committed to launch and roll-out new products; impact of CHF 850 million on EBITDA from 2016 to 2019. Strong growth expected to continue in 2018 and beyond • Net sales expected to grow more than 10% at constant exchange rates • Reported EBITDA expected to increase more than 20% • Confirmation that 2020 net sales expected to exceed CHF 2 billion and EBITDA to reach a high triple-digit level • Post-period end ferroportin inhibitor VIT-2763 entered phase-I studies

    FINANCIAL PERFORMANCE

    In million CHF FY 2017 FY 2016 Change in %
    Net sales 1,342.1 1,167.0 15.0
    EBITDA excluding launch and ramp-up of Veltassa® 511.8 434.7 17.7
    Cash net of debt 191.1 -1,832.4 n/a
    Net profit after minorities 1,147.1 237.0 384.0
    Core earnings per share 2.12 3.00 -29.3

    For further details, please see the Vifor Pharma Group 2017 Annual Report (PDF only) at www.viforpharma.com.

     For the full press release in English, please click here.

    Live conference call and webcast
    Vifor Pharma will host a live conference call (see phone numbers below) and webcast (https://edge.media-server.com/m6/p/2acgz56v) on the 15 March 2018 at 1:00 p.m. (CET). The pin code for the live conference call is 8815932.

      Phone numbers for the live conference call                          Local                                Free

    Switzerland: +41 22 567 5750 0800 222 801
    France: +33 1 76 77 2257 0805 101 278
    Germany: +49 69 2222 2018 0800 101 1732
    United Kingdom: +44 330 336 9411 0800 279 7204
    United States of America: +1 646 828 8193 888-394-8218
    Other countries: +44 330 336 9411  

    Replay

    Seite 1 von 2



    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE Vifor Pharma Ltd. / VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. In 2017 vifor pharma …